Non-exclusive discount agreement for Fampridine (Open-House model)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Fampridin (ATC-Code nach WHO: N07XX07)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No minimum volumes; actual demand is unknown and depends on physician prescribing behavior and patient numbers.
The buyer may terminate the open house if exclusive agreements are concluded, typically 8-12 months after publication.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Feb 29, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Feb 2028
- Entering into non-exclusive discount agreements for Fampridine
- No minimum purchase quantities
Show full summary
This tender invites pharmaceutical companies to enter into non-exclusive discount agreements for the active ingredient Fampridine (ATC N07XX07) under §130a SGB V via an Open-House model. All eligible companies can participate without exclusivity. No minimum purchase quantities are guaranteed, and the agreement ends by 29 February 2028. The buyer is AOK PLUS for the regions of Saxony and Thuringia. No estimated value is provided.
Risks
No minimum volumes; actual demand is unknown and depends on physician prescribing behavior and patient numbers.
The buyer may terminate the open house if exclusive agreements are concluded, typically 8-12 months after publication.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur per §4 Abs.18 AMG
- No Russian sanctions ties per EU Regulation 833/2014
Eligibility
- No exclusion grounds per §§123,124 GWB
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive discount agreement for Fampridine (Open-House model)
Establishment of a non-exclusive framework agreement for Fampridine under §130a SGB V. No minimum volumes, no exclusivity.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Fampridin (ATC-Code nach WHO: N07XX07)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 18 Dec 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 848406-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No minimum volumes; actual demand is unknown and depends on physician prescribing behavior and patient numbers.
The buyer may terminate the open house if exclusive agreements are concluded, typically 8-12 months after publication.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications